Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.

Date publication

octobre 2018

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe , Pr PETIT Thierry , Dr DESMOULINS Isabelle

Tous les auteurs :
Cabel L, Carton M, Cheaib B, Pierga JY, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30357526

Résumé

HER2-negative metastatic breast cancer (MBC) is a common setting in which chemotherapy could be effective even in later lines of treatment. Oral etoposide has demonstrated clinical activity in this setting in small-scale studies, but its efficacy has not been compared to that of other chemotherapy regimens.

Mots clés

Etoposide, Metastatic breast cancer, Oral drug

Référence

Breast Cancer Res. Treat.. 2018 Oct 24;: